Advertisement

Topics

Generex Biotechnology Corporation Announces Collaboration With Merck & Co. To Evaluate KEYTRUDA (Pembrolizumab) In Combination With AE37 In Patients With Triple-Negative Breast Cancer

20:00 EDT 30 Jul 2017 | BioSpace

  Life Sciences Jobs   ...

Original Article: Generex Biotechnology Corporation Announces Collaboration With Merck & Co. To Evaluate KEYTRUDA (Pembrolizumab) In Combination With AE37 In Patients With Triple-Negative Breast Cancer

NEXT ARTICLE

More From BioPortfolio on "Generex Biotechnology Corporation Announces Collaboration With Merck & Co. To Evaluate KEYTRUDA (Pembrolizumab) In Combination With AE37 In Patients With Triple-Negative Breast Cancer"

Quick Search
Advertisement